Mesangial accumulation of GA-pyridine, a novel glycolaldehyde-derived AGE, in human renal disease

Kidney International

Volumn 68, Issue 2, 2005, Pages 595-602

  Greven, Wendela L ^b   Waanders, Femke ^b   Nagai, Ryoji ^b   Van Den Heuvel, Marius C ^b   Navis, Gerjan ^b   Van Goor, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Avanced glycation end products; Diabetic nephropathy; Maillard; Mesangial matrix expansion; Nonenzymatic glycosylation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE DERIVATIVE; GLYCOLALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; ACETALDEHYDE; DRUG DERIVATIVE; PEROXIDASE; PYRIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; PRIORITY JOURNAL; SCORING SYSTEM; STAINING; STATISTICAL SIGNIFICANCE; ADOLESCENT; BIOPSY; CHILD; DIABETIC NEPHROPATHY; KIDNEY TUBULE; MESANGIUM; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD;

ACETALDEHYDE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHILD; CHILD, PRESCHOOL; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR MESANGIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY TUBULES; MALE; MIDDLE AGED; PEROXIDASE; PYRIDINES;

EID: 26944477067     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00437.x     Document Type: Article

References (37)

1. THORPE SR, BAYNES JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9:69-77, 1996
2. HEIDLAND A, SEBEKOVA K, SCHINZEL R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38:S100-S106, 2001
3. MIYATA T, FU MX, KUROKAWA K, et al: Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia? Kidney Int 54:1290-1295, 1998
4. SINGH R, BARDEN A, MORI T, et al: Advanced glycation end-products: A review. Diabetologia 44:129-146, 2001
5. WAGNER Z, WITTMANN I, MAZAK I, et al: N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function. Am J Kidney Dis 38:785-791, 2001
6. ALDERSON NL, CHACHICH MR, YOUSSEF NN, et al: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63:2123-2133, 2003
7. DEGENHARDT TP, ALDERSON NL, ARRINGTON DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950, 2002
8. TANJI N, MARKOWITZ GS, FU C, et al: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11:1656-1666, 2000
9. SCHMIDT AM, HASU M, POPOV D, et al: Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 91:8807-8811, 1994
10. NAGAI R, MATSUMOTO K, LING X, et al: Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 49:1714-1723, 2000
11. OHGAMI N, NAGAI R, IKEMOTO M, et al: CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 16:56-59, 2002
12. JONO T, MIYAZAKI A, NAGAI R, et al: Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 511:170-174, 2002
13. LI JH, WANG W, HUANG XR, et al: Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 164:1389-1397, 2004
14. SCHMIDT AM, YAN SD, BRETT J, et al: Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 91:2155-2168, 1993
15. SCHMIDT AM, HORI O, CHEN JX, et al: Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403, 1995
16. GLOMB MA, MONNIER VM: Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270:10017-10026, 1995
17. ANDERSON MM, REQUENA JR, CROWLEY JR, et al: The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103-113, 1999
18. NAGAI R, HAYASHI CM, XIA L, et al: Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modifled proteins. J Biol Chem 277:48905-48912, 2002
19. DIAMOND JR, KARNOVSKY MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 33:917-924, 1988
20. GUGLIUCCI A, BENDAYAN M: Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39:149-160, 1996
21. MIYATA T, UEDA Y, HORIE K, et al: Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 53:416-422, 1998
22. SUZUKI D, MIYATA T, SAOTOME N, et al: Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10:822-832, 1999
23. TAKEUCHI M, MAKITA Z, BUCALA R, et al: Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6:114-125, 2000
24. UESUGI N, SAKATA N, HORIUCHI S, et al: Glycoxidation-modified macrophages and lipid peroxidation products are associated with the progression of human diabetic nephropathy. Am J Kidney Dis 38:1016-1025, 2001
25. HORIE K, MIYATA T, MAEDA K, et al: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100:2995-3004, 1997
26. HAMELIN M, BOROT-LALOI C, FRIGUET B, et al: Increased level of glycoxidation product N(epsilon)-(carboxymethyl)lysine in rat serum and urine proteins with aging: Link with glycoxidative damage accumulation in kidney. Arch Biochem Biophys 411:215-222, 2003
27. VERBEKE P, PERICHON M, BOROT-LALOI C, et al: Accumulation of advanced glycation endproducts in the rat nephron: Link with circulating AGEs during aging. J Histochem Cytochem 45:1059-1068, 1997
28. SOULIS-LIPAROTA T, COOPER M, PAPAZOGLOU D, et al: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
29. CROWLEY ST, BROWNLEE M, EDELSTEIN D, et al: Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells. Diabetes 40:540-547, 1991
30. PUGLIESE G, PRICCI F, ROMEO G, et al: Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46:1881-1887, 1997
31. ABE H, MATSUBARA T, IEHARA N, et al: Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 279:14201-14206, 2004
32. VALENCIA JV, WELDON SC, QUINN D, et al: Advanced glycation end product ligands for the receptor for advanced glycation end products: Biochemical characterization and formation kinetics. Anal Biochem 324:68-78, 2004
33. KUNIYASU A, OHGAMI N, HAYASHI S, et al: CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS Lett 537:85-90, 2003
34. LING X, NAGAI R, SAKASHITA N, et al: Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats and in rats with streptozotocin-induced diabetes. Lab Invest 81:845-861, 2001
35. LIEUW-A-FA ML, VAN HINSBERGH VW, TEERLINK T, et al: Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: Correlation with markers of endothelial dysfunction. Nephrol Dial Transplant 19:631-636, 2004
36. VLASSARA H: Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues. Diabetes 41(Suppl 2):52-56, 1992
37. SATO N, SHIMIZU H, SUWA K, et al: MPO activity and generation of active O2 species in leukocytes from poorly controlled diabetic patients. Diabetes Care 15:1050-1052, 1992